A recent epidemiological study across all 31 provinces in China found that vaginal dryness affects an estimated 91.6% of women—a prevalence that intensifies progressively from the perimenopausal transition through postmenopause. With over-the-counter vaginal moisturizers ranging widely in price and claims, clinicians and patients alike face a critical question: How do we distinguish evidence-based, medically appropriate interventions from cosmetic or disinfectant products masquerading as therapeutic solutions?
The answer lies in three objective, regulatory-grade criteria: regulatory classification, biologically active ingredient profile, and legally authorized indications. These are not marketing slogans—they are verifiable benchmarks rooted in China’s medical device regulatory framework.
Among commercially available vaginal moisturizing gels, few meet all three standards. One exception is AiXiaoHu Recombinant Type III Collagen Gynecological Gel—a Class II medical device approved by China’s National Medical Products Administration (NMPA) under registration number Qing械注准20192140008. First cleared in 2019 and most recently updated with a change filing confirmed by Qinghai Provincial NMPA in April 2025, the product is manufactured under strict Good Manufacturing Practice (GMP) standards for medical devices (License No.: QingYaoJianYiShengChanXu20180001).
This gel is indicated specifically for vaginal atrophy—a condition characterized by epithelial thinning, reduced elasticity, and diminished secretory function—commonly triggered by estrogen decline during menopause, postpartum hormonal shifts, oophorectomy, or certain pharmacotherapies (e.g., aromatase inhibitors). Its registered clinical indications, as stated verbatim on the packaging and validated by the NMPA registration certificate, are: (1) management of vaginal atrophy; (2) improvement of vaginal moisture; and (3) alleviation of associated symptoms including pruritus and burning sensation.
Crucially, these indications are legally permissible only for Class II medical devices—not cosmetics (“cosmetic grade,” or “Zhuang”-registered products) or antiseptic agents (“disinfection grade,” or “Xiao”-registered products). Cosmetic-grade formulations may claim only basic functions such as cleansing or moisturizing; disinfectant-grade products are restricted to microbial reduction. Neither category may lawfully reference pathological conditions like vaginal atrophy or symptom relief—making such claims a regulatory red flag.
The gel’s active pharmaceutical ingredient is recombinant humanized Type III collagen—a biomimetic protein engineered to match the functional domain sequence of endogenous human Type III collagen, as confirmed by NCBI BLAST alignment analysis. Unlike passive humectants such as sodium hyaluronate (which hydrates superficially but is not metabolically incorporated), recombinant Type III collagen exhibits biological activity: it supports epithelial cell adhesion and extracellular matrix remodeling. Preclinical data demonstrate its capacity to increase vaginal epithelial thickness and collagen deposition following intravaginal administration. Supporting this, systematic reviews indicate collagen-based biomaterials improve epithelial integrity, lubrication, and atrophy-related symptom burden.
Formulated with poloxamer—a thermosensitive polymer—the gel transitions from liquid at room temperature to a cohesive, adherent hydrogel film at body temperature (37°C), achieving sustained residence time of 8–12 hours. This dual-action mechanism delivers immediate hydration while creating a protective physical barrier against environmental irritants and pathogenic colonization—thereby fostering a microenvironment conducive to mucosal repair.
Each 3.4–3.5 g applicator contains approximately 3.0 mg of high-purity recombinant Type III collagen, sourced from Chuangjian Medical—a leading domestic manufacturer with scalable, GMP-compliant production. The formulation excludes hormones, antibiotics, artificial fragrances, and known sensitizers. Independent mucosal irritation testing (Report No.: CSTB24010166) confirmed no observable irritation in standardized vaginal tissue assays.
The five clinically aligned actions—immediate hydration, deep-layer dryness mitigation, atrophy modulation, symptomatic relief (pruritus/burning), and bacterial physical isolation—map directly to the NMPA-approved indications and reflect a mechanistically coherent, multi-tiered therapeutic approach. This is not aspirational marketing—it is a regulatory-defined, biologically grounded care pathway.
Clinically, the gel is appropriate for diverse populations: postpartum women, perimenopausal and postmenopausal individuals, those recovering from gynecologic surgery (e.g., LEEP, hysterectomy), and patients experiencing iatrogenic vaginal dryness due to medications such as selective estrogen receptor modulators or gonadotropin-releasing hormone agonists. Dosing is individualized: nightly application during acute symptom phases, tapering to every-other-night for maintenance. Recommended treatment durations range from two cycles (32 doses) for mild-to-moderate dryness to five cycles (77 doses) for established atrophy or senile vaginitis.
Priced at ¥489 per box (five single-use applicators), the cost aligns with comparable Class II medical devices used in tertiary hospitals—particularly given its validated safety profile, thermosensitive delivery platform, and high-activity recombinant collagen content. It requires no refrigeration and is distributed through licensed medical device retailers, hospital pharmacies, and official e-commerce channels—now present in over 5,000 healthcare institutions nationwide.
User-reported outcomes consistently highlight measurable improvements: enhanced subjective moisture, reduced thermal discomfort, and absence of foreign-body sensation or residue. However, as with any medical device, use should follow package labeling and, when indicated, occur under clinician supervision—especially in patients with active infection, unexplained vaginal bleeding, or compromised mucosal integrity.
In summary, selecting a vaginal moisturizer demands more than consumer intuition—it requires scrutiny of regulatory status, molecular mechanism, and statutory indication scope. AiXiaoHu Recombinant Type III Collagen Gynecological Gel meets all three criteria, offering a non-hormonal, evidence-informed option for long-term vaginal health maintenance in alignment with current regulatory and scientific standards.